# PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT02049593** · PHASE1 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 44 (actual)

## Conditions studied

- Metastatic Cancer
- Unspecified Adult Solid Tumor

## Interventions

- **DRUG:** PARP inhibitor BMN-673
- **DRUG:** temozolomide
- **DRUG:** irinotecan hydrochloride
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02049593
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-12
- **Primary completion:** 2019-10-07
- **Final completion:** 2019-10-07
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2022-09-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02049593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02049593, "PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02049593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*